RxDoctor Payments Data

Alessandra Ferrera, MD

Psychiatry · West Palm Beach, FLNPI 1730676248

Payments from drug & device makers

$4,990in general payments, 2019–2025

Across 210 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$697
  • Alkermes, Inc.$638
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$539
  • Johnson & Johnson$494
  • AbbVie$391
  • Neurocrine Biosciences, Inc.$346
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,990100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,990 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$85,031
Medicare patients
96
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant11$4,697
Clozapine23$4,215
Aripiprazole23$2,939
Mirtazapine74$2,388
Lisdexamfetamine Dimesylate11$2,213
Duloxetine Hcl65$1,385
Bupropion XlBupropion Hcl65$1,306
Escitalopram Oxalate109$1,183
Buspirone Hcl74$1,102
Sertraline Hcl90$910
Vilazodone Hcl16$877
Trazodone Hcl100$838
Quetiapine Fumarate35$702
Alprazolam120$637
Hydroxyzine Hcl16$606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$35$4,69711 claims
Almatica Pharma LLCSertraline Hcl$293$91090 claims
Teva Pharmaceuticals USA, Inc.Loxapine$285$26612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →